ACC

ACC.24: Icosapent ethyl was associated with reduced rate of MACE at all baseline levels of Lp(a) in participants with elevated TG and at high risk for CVD.

ACC.24: Data from an analysis of the CLEAR Outcomes trial showed bempedoic acid was well-tolerated and reduced CV events in Hispanic/Latinx and non-Hispanic/Latinx participants.

CLEAR Outcomes PI Steven Nissen, MD, links findings from the pivotal trial with labeling updates that make bempedoic acid the only nonstatin agent approved to reduce CV risk.

ACC.24: Findings showed a disproportionate distribution of CAC screening that favors White, educated, affluent, English-speaking individuals.

ACC.2024: In a cohort of people at high risk of ASCVD, three-quarters achieved target LDL-C levels at 6 months and 12 months while using a remote algorithm-directed program.

ACC 2023. Electronic nudges highlighting the potential cardiovascular benefits of flu vaccination led to a modest uptake in vaccination rates among older adults in Denmark, according to results of the NUDGE-FLU trial.

ACC2023. Risk for MACE was nearly 7-fold higher in participants on a keto diet whose LDL-C was already high compared with those on a standard diet with LDL-C in a normal range.

ACC 2023. In the CLEAR Outcomes trial, bempedoic acid reduced risk for major CV events by 13% compared with placebo in patients who had, or were at high risk for, CVD.

ACC2023. For high-risk T2D patients not receiving optimal treatment for hyperlipidemia, hypertension, or hyperglycemia, intensive, multidisciplinary training for clinic staff could shift practice.

ACC 2023. The Mediterranean diet has a beneficial effect on the primary prevention of cardiovascular disease and death in women, according to new analysis.